Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α

Hagop M. Kantarjian*, Jorge E. Cortes, Susan O'Brien, Rajyalakshmi Luthra, Francis Giles, Srdan Verstovsek, Stefan Faderl, Deborah Thomas, Guillermo Garcia-Manero, Mary Beth Rios, Jianqin Shan, Dan Jones, Moshe Talpaz

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

149 Scopus citations

Fingerprint Dive into the research topics of 'Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds